Neo Ivy Capital Management Buys New Position in Edwards Lifesciences Co. (NYSE:EW)

Neo Ivy Capital Management purchased a new position in Edwards Lifesciences Co. (NYSE:EW - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,002 shares of the medical research company's stock, valued at approximately $726,000.

Other hedge funds also recently modified their holdings of the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter valued at about $30,000. Prospera Private Wealth LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its stake in Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock valued at $35,000 after acquiring an additional 308 shares in the last quarter. HHM Wealth Advisors LLC acquired a new position in Edwards Lifesciences during the 2nd quarter worth approximately $55,000. Finally, Peoples Bank KS bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EW. Jefferies Financial Group downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and lowered their target price for the stock from $85.00 to $70.00 in a report on Wednesday, September 18th. UBS Group lowered their price objective on shares of Edwards Lifesciences from $90.00 to $75.00 and set a "neutral" rating on the stock in a research note on Tuesday, September 10th. JPMorgan Chase & Co. raised their target price on shares of Edwards Lifesciences from $72.00 to $78.00 and gave the company a "neutral" rating in a research note on Friday, October 25th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday. Finally, Oppenheimer restated an "outperform" rating and issued a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Seventeen research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has an average rating of "Hold" and an average target price of $78.65.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now owns 198,526 shares of the company's stock, valued at $13,084,848.66. This represents a 11.18 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 35,000 shares of company stock valued at $2,323,150. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Trading Up 0.2 %

Shares of NYSE:EW traded up $0.16 during mid-day trading on Thursday, reaching $73.97. 3,748,126 shares of the company's stock were exchanged, compared to its average volume of 4,649,521. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The firm has a market capitalization of $43.63 billion, a price-to-earnings ratio of 10.67, a PEG ratio of 3.52 and a beta of 1.12. The business's fifty day moving average price is $69.09 and its 200-day moving average price is $74.19.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the company earned $0.59 earnings per share. The firm's revenue was up 8.9% compared to the same quarter last year. On average, research analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.